Date of Award
Summer 8-2021
Document Type
Thesis
Degree Name
Master of Science (MS)
Department
Pharmaceutical Sciences
First Advisor
Enrique Seoane-Vazquez
Second Advisor
Rosa Rodriguez-Monguio
Third Advisor
Lawrence M. Brown
Abstract
Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. Material and Methods
Clinical data were collected from the FDA databases, RedBook online, National Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost information was extracted from the Redbook and published studies. The cost-effective analysis was performed using TreeAge Pro (Healthcare Version) version 2021. Results
The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Recommended Citation
Lotfi, K. Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia. [master’s thesis]. Irvine, CA: Chapman University; 2021. https://doi.org/ 10.36837/chapman.000294
Included in
Health Services Research Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Patient Safety Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons